TGFB1 and chronic kidney disease: Targeting fibrosis remains the main goal to treat CKD; however, most anti-fibrotic therapies such as transforming growth factor-β (TGF-β), a master player in the pathogenesis of renal inflammation and fibrosis [8], have proven disappointing [9,10,11].